Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the Article8th Circuit ruling
3 storiesS-1 public filing
1 storyRate reaches all other companies Sep 29
1 storyNon-renewal notice deadline Oct 2
2 storiesPreliminary injunction briefs due Oct 5
The final rule that keeps the end of race- and sex-based DBE presumptions now sets December 24, 2026 for certifiers to finish reevaluations and March 24, 2027 to cut off firms that never answer.
The administration asked the justices to let third-country deportations resume while it appeals, and its central example of harm is a canceled flight carrying 70 people to three countries.
The Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis came in at p=0.0603, just past the threshold. Acadia is dropping the low dose, rewriting who qualifies for the late-stage trials, and continuing.
Dr. Heidi Overton affirmed vaccine safety at her confirmation hearing, declined to contradict the president on the measles shot, and sidestepped questions about the abortion pill she once called dangerous.
New Zealand's central bank ordered an independent report into how TSB calculated its capital and liquidity ratios, and the answer arrives after shareholders decide whether to approve the bank's sale.
A federal judge ordered CNN, MS NOW and Politico credentials restored within hours of the White House taking them, and by evening the same outlets were still outside the room where the president received China's leader.
A ransomware gang says it took 2.5 terabytes from a Maryland mortgage lender. Five federal suits were filed while the notification deadlines that bind the lender were still open.
A September 24 request for information asks whether the standards for reasonable and relevant pharmacy contracts should include reimbursement methodologies, with comments due November 23 and the standards required by April 2028.
A Commerce notice defines the nine drug categories that can enter the United States at a zero rate under the Section 232 pharmaceutical tariffs, names the 19 jurisdictions eligible for them, and opens a one-product-at-a-time application process.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article